For research use only. Not for therapeutic Use.
Lys(CO-C3-p-I-Ph)-OMe (Cat No.: I040017) is a modified lysine derivative used in peptide synthesis, medicinal chemistry, and radiopharmaceutical research. The para-iodophenyl (p-I-Ph) moiety enables bioorthogonal conjugation and radiolabeling applications, making it valuable for imaging and targeted drug delivery studies. The methyl ester (OMe) group provides stability and solubility, facilitating incorporation into peptide sequences. This compound is widely applied in designing peptide-based probes, radiotracers, and novel therapeutic agents for cancer, metabolic disorders, and biomedical research in targeted diagnostics and therapy.
| CAS Number | 2088426-96-2 |
| Synonyms | methyl (2S)-2-amino-6-[4-(4-iodophenyl)butanoylamino]hexanoate |
| Molecular Formula | C17H25IN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H25IN2O3/c1-23-17(22)15(19)6-2-3-12-20-16(21)7-4-5-13-8-10-14(18)11-9-13/h8-11,15H,2-7,12,19H2,1H3,(H,20,21)/t15-/m0/s1 |
| InChIKey | VDKOYQQVPOAMHS-HNNXBMFYSA-N |
| SMILES | COC(=O)C(CCCCNC(=O)CCCC1=CC=C(C=C1)I)N |
| Reference | [1]. Sun M, et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Curr Oncol Rep. 2021 Mar 29;23(5):59. [2]. Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. Cancer Research, 2024, 84(6_Supplement): 6033-6033. |
